

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13                   UNITED STATES DISTRICT COURT  
14                   WESTERN DISTRICT OF WASHINGTON  
15                   AT SEATTLE

16  
17                   PACIFIC BIOSCIENCE  
18                   LABORATORIES, INC., a Washington  
19                   corporation,

20                   Plaintiff,

21                   v.

22                   RN VENTURES LTD., a United Kingdom  
23                   corporation,

24                   Defendant.

25                   No.

26                   COMPLAINT FOR PATENT  
27                   INFRINGEMENT

28                   **JURY DEMAND**

31  
32                   Plaintiff Pacific Bioscience Laboratories, Inc. (“PBL”), for its Complaint for Patent  
33                   Infringement against Defendant RN Ventures Ltd., (“RN Ventures”), hereby alleges, by and  
34                   through its attorney, on personal knowledge as to its own actions and on information and belief  
35                   as to the actions of others, as follows:

36                   **I. INTRODUCTION**

37                   1. Plaintiff PBL dramatically changed the market for skin cleansing products when it  
38                   introduced its innovative Clarisonic Sonic Skin Cleansing System (the “Clarisonic System”) in  
39                   2004. The Clarisonic System employs motion and forces at sonic frequencies to cleanse, soften,  
40                   and smooth skin.

1       2. Prior to the introduction of the Clarisonic System, there were no sonic facial  
 2       cleansing devices on the market. PBL created today's market for such products.  
 3  
 4

5       3. The Clarisonic System has been an enormous success and has achieved national  
 6       recognition and awards. In 2010, PBL was named one of Inc. 500's Fastest Growing Private  
 7       Companies.  
 8  
 9

10      4. PBL received broad protection for its innovations, including utility and design  
 11     patents. However, PBL's innovations have been the subject of widespread imitation by others,  
 12     who have attempted to capitalize on PBL's success.  
 13  
 14

15      5. Defendant RN Ventures is one such imitator. After seeing PBL's success, RN  
 16     Ventures introduced its Magnitone Pulsar facial cleansing system ("Magnitone Pulsar"). RN  
 17     Ventures has made the Magnitone Pulsar work and look like PBL's products, thereby infringing  
 18     PBL's patents.  
 19  
 20

21      6. RN Ventures sells or has sold the Magnitone Pulsar throughout the United States  
 22     at least through the Magnitone website, <https://magnitone.co.uk/shop/magnitone-pulsar/>, and  
 23     other websites, such as [http://www.lookfantastic.com/magnitone-pulsar-daily-skin-cleansing-](http://www.lookfantastic.com/magnitone-pulsar-daily-skin-cleansing-toning-and-exfoliation-brush-for-face-and-body/10858382.html)  
 24     [toning-and-exfoliation-brush-for-face-and-body/10858382.html](http://www.lookfantastic.com/magnitone-pulsar-daily-skin-cleansing-toning-and-exfoliation-brush-for-face-and-body/10858382.html).  
 25  
 26

27      7. PBL seeks to stop RN Ventures' infringing conduct and obtain compensation for  
 28     the violations that have occurred thus far.  
 29  
 30

## 31                   II. PARTIES

32      8. Plaintiff PBL is a Washington corporation incorporated in January 2001, with its  
 33     principal place of business at 17275 NE 67th Court, Redmond, WA 98052.  
 34  
 35

36      9. In December 2011, PBL was acquired by L'Oréal S.A., a French société anonyme  
 37     ("L'Oréal"). L'Oréal is the owner, and PBL is the exclusive U.S. licensee with the right, *inter*  
 38     *alia*, to bring suit, of protectable patent rights as described herein.  
 39  
 40

10. On information and belief, RN Ventures Ltd. is a corporation organized and existing under the laws of the United Kingdom with its principal place of business at Francis House, 10 Francis Street, London SW1P 1DE, United Kingdom.

11. On information and belief, RN Ventures manufactures, markets, and sells electric skin care devices under the name Magnitone Pulsar.

### **III. JURISDICTION AND VENUE**

12. This case arises under the patent laws of the United States, 35 U.S.C. § 101 et seq.

13. The Court has subject matter jurisdiction over this case pursuant to 28 U.S.C. §§ 1331, 1332, and 1338.

14. PBL has its principal place of business in this District, and makes its Clarisonic devices available for sale in this District.

15. This Court has personal jurisdiction over RN Ventures because, on information and belief, RN Ventures has committed and continues to commit the acts violating PBL's intellectual property described herein within the State of Washington, including in this District, and places infringing products into the stream of commerce, with the knowledge or understanding that such products are sold in the State of Washington, including in this District.

16. Venue is proper in this District pursuant to 28 U.S.C. § 1331, 28 U.S.C. § 1332, and 28 U.S.C. § 1333 because, *inter alia*, PBL's principal place of business is within this District and PBL suffered harm in this District, because a substantial part of the events giving rise to the claims against RN Ventures occurred and are occurring in this District, and because RN Ventures transacts business within this District and offers for sale in this District products that infringe PBL's intellectual property.

#### IV. BACKGROUND

17. Since the early 2000s, PBL has designed, developed, manufactured, marketed, and sold in the United States (and worldwide) its innovative Clarisonic System, which is a line of skin care products including a number of Sonic Cleansing Brushes and accessories, the

**Perkins Coie LLP**  
1201 Third Avenue, Suite 4900  
Seattle, WA 98101-3099  
Phone: 206.359.8000  
Fax: 206.359.9000

1 Clarisonic Opal® Sonic Infusion System, and targeted treatment solutions. Examples of  
 2 Clarisonic products are pictured below:  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18



19  
 20       18. The Clarisonic System was developed by PBL over many years at great expense  
 21 and effort and represents a breakthrough in devices and methods for treatment of early stage acne  
 22 and for effective cleansing of skin. Those devices and methods employ motion and forces at  
 23 sonic frequencies to cleanse, soften, and smooth skin. They alleviate clogged pores and remove  
 24 debris from skin more gently and effectively than alternative devices or methods, such as manual  
 25 cleansing.  
 26  
 27  
 28  
 29  
 30

31       19. The innovations embodied in the Clarisonic System are protected by numerous  
 32 United States and foreign intellectual property rights, including rights deriving from patents.  
 33  
 34

35       20. Prior to the introduction of the Clarisonic System, there were no sonic facial  
 36 cleansing devices on the market. Indeed, before development of the Clarisonic System, no  
 37 market existed for sonic skin care devices. PBL expended considerable resources to create the  
 38 sonic skin care market and to educate the public regarding facial cleansing, as well as to market  
 39 its sonic facial cleansing devices.  
 40  
 41  
 42  
 43  
 44

45       21. Since its introduction, the Clarisonic System has become widely acclaimed by  
 46 professionals and consumers, and has garnered many media awards from sources such as  
 47 authoritative magazines in the beauty industry, Oprah's Favorite Things in 2007 on the Oprah  
 48  
 49  
 50  
 51

**Perkins Coie LLP**  
 1201 Third Avenue, Suite 4900  
 Seattle, WA 98101-3099  
 Phone: 206.359.8000  
 Fax: 206.359.9000

Winfrey Show, Best of Sephora in 2007 and 2008, and QVC Customer Choice in 2008, 2009, and 2010.

22. The success of the Clarisonic System has spurred a large number of imitations, such as RN Ventures' Magnitone Pulsar, pictured below.



## V. PBL'S PATENTS

U.S. Patent No. 7,320,691

23. U.S. Patent No. 7,320,691 ("the '691 patent") issued on January 22, 2008, and is entitled "Apparatus and Method for Acoustic/Mechanical Treatment of Early Stage Acne." The inventors are Kenneth A. Pilcher, David Giuliani, and Stephen M. Meginniss.

24. A copy of the '691 patent is attached as Exhibit 1.

25. PBL is the exclusive licensee having all substantial rights in and to the '691 patent, with the rights to bring enforcement actions for past, present and future infringement and to collect damages for past infringement.

26. The '691 patent has been reexamined pursuant to Reexamination Request Nos. 90/009,797 and 90/011,343. The patentability of all of the originally issued claims 1-52 of the '691 patent was confirmed pursuant to these reexamination requests, and claims 53-64 were added. A reexamination certificate issued on September 20, 2011. *See* Exhibit 1.

**Perkins Coie LLP**  
1201 Third Avenue, Suite 4900  
Seattle, WA 98101-3099  
Phone: 206.359.8000  
Fax: 206.359.9000

1       27. The '691 patent is valid, enforceable, and currently in full force and effect.  
 2  
 3  
 4

**U.S. Patent No. D523,809**

5       28. U.S. Patent No. D523,809 ("the D'809 patent") issued on June 27, 2006, and is  
 6       entitled "Charger for an Electric Skin Brush." The inventors are Dane M. Roth, Robert E.  
 7  
 8       Akridge, and Kenneth A. Pilcher.  
 9  
 10

11       29. A copy of the D'809 patent is attached as Exhibit 2.  
 12  
 13

14       30. PBL is the exclusive licensee having all substantial rights in and to the D'809  
 15       patent, with the rights to bring enforcement actions for past, present and future infringement and  
 16       to collect damages for past infringement.  
 17  
 18

19       31. The D'809 patent is valid, enforceable, and currently in full force and effect.  
 20  
 21

**CLAIM I – INFRINGEMENT OF THE '691 PATENT**

22       32. PBL hereby incorporates and realleges Paragraphs 1 - 31 as if fully set forth  
 23       herein.  
 24  
 25

26       33. RN Ventures has been and/or is directly infringing one or more claims of the '691  
 27       patent pursuant to 35 U.S.C. § 271(a), literally or under the doctrine of equivalents, by making,  
 28       using, offering to sell, and/or selling in the United States and/or importing into the United States,  
 29       products, devices, or systems that are covered by the '691 patent, including the Magnitone  
 30       Pulsar.  
 31  
 32

33       34. PBL has consistently and continuously marked its products with the '691 patent  
 34       number pursuant to 35 U.S.C. § 287 and has provided constructive notice of the '691 patent.  
 35       PBL seeks monetary and all other damages permitted by statute.  
 36  
 37

38       35. RN Ventures' infringement of the '691 patent has been and will continue to be  
 39       willful and deliberate, by making, using, offering to sell, and/or selling in the United States  
 40       and/or importing into the United States, infringing devices despite that such actions constitute  
 41       infringement and despite being at least on constructive notice that its actions constitute  
 42       infringement.  
 43  
 44


**Perkins Coie LLP**  
 1201 Third Avenue, Suite 4900  
 Seattle, WA 98101-3099  
 Phone: 206.359.8000  
 Fax: 206.359.9000

36. RN Ventures' infringement of the '691 patent has caused and will continue to cause PBL substantial and irreparable injury, for which PBL is entitled to all of the relief provided by 35 U.S.C. §§ 281, 283, 284, and 285, including but not limited to injunctive relief, compensatory damages not less than the amount of a reasonable royalty, interest, costs, enhanced damages, and reasonable attorney's fees, as the court deems just and appropriate.

## **CLAIM II – INFRINGEMENT OF THE D'809 PATENT**

37. PBL hereby incorporates and realleges Paragraphs 1 - 36 as if fully set forth herein.

38. RN Ventures has been and/or is directly infringing the D'809 patent pursuant to 35 U.S.C. § 271(a), by making, using, offering to sell, and/or selling in the United States and/or importing into the United States, products, devices, or systems that embody the design covered by the D'809 patent, including the Magnitone Pulsar.



39. PBL has consistently and continuously marked its products with the D'809 patent number pursuant to 35 U.S.C. § 287 and has provided constructive notice of the D'809 patent. PBL seeks monetary and all other damages permitted by statute.

**COMPLAINT FOR PATENT INFRINGEMENT – 7**  
116576-8901/LEGAL125870072.1

**Perkins Coie LLP**  
1201 Third Avenue, Suite 4900  
Seattle, WA 98101-3099  
Phone: 206.359.8000  
Fax: 206.359.9000

1           40. RN Ventures' infringement of the D'809 patent has been and will continue to be  
 2 willful and deliberate, by making, using, offering to sell, and/or selling in the United States  
 3 and/or importing into the United States, infringing devices despite that such actions constitute  
 4 infringement and despite being at least on constructive notice that its actions constitute  
 5 infringement.  
 6  
 7  
 8  
 9

10          41. RN Ventures' infringement of the D'809 patent has caused and will continue to  
 11 cause PBL substantial and irreparable injury, for which PBL is entitled to all of the relief  
 12 provided by 35 U.S.C. §§ 281, 283, 284, 285, and 289, including but not limited to injunctive  
 13 relief, compensatory damages not less than the amount of a reasonable royalty, interest, costs,  
 14 enhanced damages, RN Ventures' profits, and reasonable attorney's fees, as the court deems just  
 15 and appropriate.  
 16  
 17  
 18  
 19  
 20  
 21

## 22                 **VI. DEMAND FOR JURY TRIAL**

23          Pursuant to Rule 38 of the Federal Rules of Civil Procedure, PBL respectfully requests a  
 24 trial by jury of all issues properly triable by jury.  
 25  
 26  
 27

## 28                 **VII. PRAYER FOR RELIEF**

29          WHEREFORE, PBL prays for relief, as follows:  
 30  
 31

- 32          A. A judgment that RN Ventures has infringed one or more claims of the '691  
 33 patent;  
 34  
 35          B. A judgment that RN Ventures has infringed the D'809 patent;  
 36  
 37          C. An order and judgment preliminarily and permanently enjoining RN Ventures and  
 38 its officers, directors, agents, servants, employees, affiliates, attorneys, and all others acting in  
 39 privity or in concert with them, and their investors, partners, parents, subsidiaries, divisions,  
 40 successors, and assigns, from further acts of infringement of PBL's asserted patents;  
 41  
 42          D. A judgment awarding PBL all damages adequate to compensate for RN Ventures'  
 43 infringement of PBL's asserted patents and/or RN Ventures' total profits pursuant to 35 U.S.C.  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51

**Perkins Coie LLP**  
 1201 Third Avenue, Suite 4900  
 Seattle, WA 98101-3099  
 Phone: 206.359.8000  
 Fax: 206.359.9000

1       § 289, and in no event less than a reasonable royalty for RN Ventures' acts of infringement,  
2 including all pre-judgment and post-judgment interest at the maximum rate permitted by law;  
3  
4

5           E.      A judgment declaring that RN Ventures' infringement of the asserted patents has  
6 been willful and deliberate;

7           F.      A judgment awarding PBL all damages, including treble damages, as a result of  
8 RN Ventures' willful and deliberate infringement of the asserted patents, pursuant to 35 U.S.C.  
9 § 284, together with pre-judgment and post-judgment interest;

10          G.     A judgment declaring that this case is exceptional and awarding PBL its expenses,  
11 costs, and attorney's fees in accordance with 35 U.S.C. §§ 284 and 285 and Rule 54(d) of the  
12 Federal Rules of Civil Procedure; and

13          H.     Such other and further relief as the Court deems just and proper.

14  
15          DATED: May 1, 2015

16  
17          Respectfully submitted,

18  
19           By: s/ Ramsey M. Al-Salam  
20           Ramsey M. Al-Salam WSBA #18822  
21           **Perkins Coie LLP**  
22           1201 Third Avenue, Suite 4900  
23           Seattle, WA 98101-3099  
24           Tel: (206) 359-8000  
25           Fax: (206) 359-9000  
26           Email: RAAlsalam@perkinscoie.com

27  
28           Attorneys for Plaintiff  
29           Pacific Bioscience Laboratories, Inc.

1  
2 COUNSEL:  
3  
4 Robert M. Masters (*pro hac to be submitted*)  
5 Timothy P. Cremen (*pro hac to be submitted*)  
6 Lisa Y. Leung (WSBA No. 43015)  
7 PAUL HASTINGS LLP  
8 875 15th St. NW  
9 Washington, D.C. 20005  
10 Tel: (202) 551-1700  
11 Fax: (202) 551-1705  
12 robertmasters@paulhastings.com  
13 timothy.cremen@paulhastings.com  
14 lisaleung@paulhastings.com  
15  
16 Robert L. Sherman (*pro hac to be submitted*)  
17 Natalie G. Furman (*pro hac to be submitted*)  
18 PAUL HASTINGS LLP  
19 75 East 55th Street  
20 New York, NY 10022  
21 Tel: (212) 318-6000  
22 Fax: (212) 230-7841  
23 robertsherman@paulhastings.com  
24 nataliefurman@paulhastngs.com  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51